沙美特罗替卡松联合白三烯受体拮抗剂治疗对重度COPD患者稳定期IC变化影响.docVIP

沙美特罗替卡松联合白三烯受体拮抗剂治疗对重度COPD患者稳定期IC变化影响【摘要】　目的：研究重度慢性阻塞性肺疾病(Chronic obstructive pulmonary disease，COPD)患者使用沙美特罗替卡松联合白三烯受体拮抗剂(Leukotriene receptor antagonists，LTRA)及单独使用沙美特罗替卡松治疗前后深吸气量的变化。方法：选取60例重度COPD患者随机分为观察组(n=30)及对照组(n=30)，观察组给予沙美特罗替卡松(500 μg/50 μg)早晚各一次吸入联合白三烯受体拮抗剂(10 mg)上午口服一次，对照组给予沙美特罗替卡松沙美特罗替卡松(500μg/50μg)早晚各一次吸入，两组治疗6个月。在治疗前、治疗3个月、6个月后行肺功能检测、IC(inspiratory capacity，IC)检测；同时采用6 min步行距离评价运动能力，呼吸困难指数mmRC评价生活质量。结果：在治疗3个月及6个月观察组IC优于对照组(P0.05)；在各治疗阶段呼吸困难指数mmRC观察组均优于对照组(P0.05)。结论：沙美特罗替卡松联合白三烯受体拮抗剂治疗重度COPD较单用沙美特罗替卡松对IC肺功能和生活质量的改善作用更明显，早期改善COPD的运动耐量，延缓肺功能的下降。 【关键词】　慢性阻塞性肺疾病；　深吸气量；　沙美特罗替卡松；　白三烯受体拮抗剂 The Influence of Therapy with Salmeterol Fluticasone Propionate Combined with Leukotriene Receptor Antagonists for the IC Change of Severe COPD Patients in Stable Phase /TAO Shao-hua，CHEN Pei，YANG Xun.//Medical Innovation of China，2012，9(25):001-003 【Abstract】Objective:To study severe Chronic obstructive pulmonary disease (COPD) patients with inhalation hormones combined LTRA and inhaled corticosteroids alone before and after the changes of the IC.Method: Selected 60 patients with moderate to severe COPD were randomly divided into observation group (n=30) and control group (n=30).The observation group was given SFC(50 μg/500 μg) inhaling twice daily comined with LTRA (10 mg) once daily， The control group was given SFC (500 μg/50 μg) twice daily. Treatment in both groups for 6 months，determined the Pulmonary function testing and IC testing before treatment and after 3 months、6 months.Over the same period using the 6 min walk distance evaluation of exercise capacity，dyspnea index mmRC evaluate the quality of life.Result:The treatment of 3 months and 6 months of observation group IC than the control group(P0.05);in various stages of treatment dyspnea index mmRC observation group than the control group (P0.05).Conclusion:IC lung function and quality of life of the improvement is more obvious，the early improvement in exercise tolerance in COPD.Slowing lung function decline